Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis acquires NLRP3 inflammasome-focused IFM Tre for up to $1.58bn

Executive Summary

Novartis AG announced a definitive agreement to acquire privately held IFM Therapeutics LLC's anti-inflammatory medicines-focused IFM Tre subsidiary for up to $1.58bn. The transaction is expected to close in Q2 2019.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register